{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:09:59Z","timestamp":1793329799774,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016338","name":"Imperial Experimental Cancer Medicine Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023178","name":"Cancer Treatment and Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023178","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024063","name":"National Health Service Corps","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 MD012565"],"award-info":[{"award-number":["R01 MD012565"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA256977"],"award-info":[{"award-number":["R01CA256977"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1053\/j.gastro.2025.03.047","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:01:30Z","timestamp":1746183690000},"page":"585-599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma"],"prefix":"10.1053","volume":"169","author":[{"given":"Amit G.","family":"Singal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2025.03.047_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: Global Burden of Disease Study","volume":"82","author":"Tan","year":"2025","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.gastro.2025.03.047_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib4","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.cgh.2023.01.039","article-title":"Breakthroughs in hepatocellular carcinoma therapies","volume":"21","author":"Singal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.03.047_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.03.047_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial","volume":"69","author":"Finn","year":"2018","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib9","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/apt.13904","article-title":"The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development","volume":"45","author":"Pinato","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.03.047_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib11","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1038\/s41388-020-1249-9","article-title":"Immune-based therapies for hepatocellular carcinoma","volume":"39","author":"Pinato","year":"2020","journal-title":"Oncogene"},{"key":"10.1053\/j.gastro.2025.03.047_bib12","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.03.047_bib13","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real\u2013world study","volume":"76","author":"D'Alessio","year":"2022","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.03.047_bib14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejca.2022.08.024","article-title":"Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study","volume":"175","author":"Fulgenzi","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.gastro.2025.03.047_bib15","first-page":"1","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2021","journal-title":"N Engl J Med Evidence"},{"key":"10.1053\/j.gastro.2025.03.047_bib16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102179","article-title":"Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"63","author":"Kulkarni","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1053\/j.gastro.2025.03.047_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101431","article-title":"Efficacy of atezolizumab plus bevacizumab for unresectable HCC: systematic review and meta-analysis of real-world evidence","volume":"7","author":"Manfredi","year":"2025","journal-title":"JHEP Reports"},{"key":"10.1053\/j.gastro.2025.03.047_bib19","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomized, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"The Lancet"},{"key":"10.1053\/j.gastro.2025.03.047_bib20","article-title":"Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials","volume":"5","author":"Fulgenzi","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1053\/j.gastro.2025.03.047_bib21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2025.03.047_bib22","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(23)00468-0","article-title":"Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study","volume":"24","author":"Zeng","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/gutjnl-2024-332837","article-title":"Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma","volume":"74","author":"Salie","year":"2025","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.03.047_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4010","article-title":"Results from the MORPHEUS-liver study: phase Ib\/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)","volume":"41","author":"Finn","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib25","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.03.047_bib26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiology.148.2.6306721","article-title":"Hepatic artery embolization in 120 patients with unresectable hepatoma","volume":"148","author":"Yamada","year":"1983","journal-title":"Radiology"},{"key":"10.1053\/j.gastro.2025.03.047_bib27","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.03.047_bib28","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.03.047_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.03.047_bib30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.cgh.2007.04.021","article-title":"A phase I\/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead","volume":"5","author":"Poon","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1053\/j.gastro.2025.03.047_bib32","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","article-title":"Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design","volume":"56","author":"Burrel","year":"2012","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib33","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/01.RVI.0000233785.75257.9A","article-title":"Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations","volume":"17","author":"Salem","year":"2006","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.gastro.2025.03.047_bib34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","article-title":"Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group","volume":"50","author":"Salem","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.gastro.2025.03.047_bib35","first-page":"1673","article-title":"Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres","volume":"41","author":"Dancey","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/j.gastro.2025.03.047_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.21980","article-title":"Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis","volume":"47","author":"Kulik","year":"2008","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.03.047_bib37","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib38","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib39","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.29691","article-title":"Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience","volume":"68","author":"Salem","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.03.047_bib40","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jvir.2022.11.036","article-title":"Radioembolization for intermediate-stage hepatocellular carcinoma maintains liver function and permits systemic therapy at progression","volume":"34","author":"Ranganathan","year":"2023","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.gastro.2025.03.047_bib41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/jso.20609","article-title":"Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation","volume":"94","author":"Kulik","year":"2006","journal-title":"J Surg Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib42","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","article-title":"A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization","volume":"9","author":"Lewandowski","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1053\/j.gastro.2025.03.047_bib43","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","article-title":"Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection","volume":"59","author":"Vouche","year":"2013","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/hpb.12095","article-title":"Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension","volume":"16","author":"Fernandez-Ros","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1053\/j.gastro.2025.03.047_bib45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/hep.27057","article-title":"Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy","volume":"60","author":"Vouche","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.03.047_bib46","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study","volume":"7","author":"Kim","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib47","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jvir.2023.02.030","article-title":"Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: a comparative study of the effectiveness, safety, and dosimetry of glass-based versus resin-based microspheres","volume":"34","author":"Villalobos","year":"2023","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.gastro.2025.03.047_bib48","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jvir.2024.10.034","article-title":"Yttrium-90 radioembolization has become the most utilized bridging treatment for liver transplant candidates in the United States","volume":"36","author":"Salem","year":"2025","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.gastro.2025.03.047_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib50","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY Study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.03.047_bib51","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","article-title":"Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants","volume":"48","author":"Gabr","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.gastro.2025.03.047_bib52","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00259-023-06111-9","article-title":"Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study","volume":"50","author":"Kokabi","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.gastro.2025.03.047_bib53","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","article-title":"Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization","volume":"11","author":"Salem","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib54","first-page":"49","article-title":"Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres","volume":"3","author":"Goin","year":"2004","journal-title":"World J Nucl Med"},{"key":"10.1053\/j.gastro.2025.03.047_bib55","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1148\/radiol.2016160718","article-title":"Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study","volume":"283","author":"Biederman","year":"2017","journal-title":"Radiology"},{"key":"10.1053\/j.gastro.2025.03.047_bib56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jvir.2017.08.026","article-title":"Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma","volume":"29","author":"Biederman","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.gastro.2025.03.047_bib57","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/liv.12637","article-title":"In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?","volume":"35","author":"El Fouly","year":"2015","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2025.03.047_bib58","first-page":"49","article-title":"Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemo-embolization versus Yttrium-90 glass microspheres","volume":"3","author":"Goin","year":"2004","journal-title":"World J Nucl Med"},{"key":"10.1053\/j.gastro.2025.03.047_bib59","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","article-title":"Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma","volume":"140","author":"Salem","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.03.047_bib60","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.03.047_bib61","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejrad.2017.05.022","article-title":"Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization","volume":"93","author":"Gabr","year":"2017","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.gastro.2025.03.047_bib62","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jvir.2017.02.018","article-title":"Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study","volume":"28","author":"Padia","year":"2017","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.gastro.2025.03.047_bib63","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"(90)Y Radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"10.1053\/j.gastro.2025.03.047_bib64","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cam4.5125","article-title":"TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis","volume":"12","author":"Brown","year":"2023","journal-title":"Cancer Med"},{"key":"10.1053\/j.gastro.2025.03.047_bib65","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00261-024-04573-5","article-title":"TACE vs. TARE for HCC \u22658 cm: a propensity score analysis","volume":"50","author":"Phan","year":"2025","journal-title":"Abdom Radiol (NY)"},{"key":"10.1053\/j.gastro.2025.03.047_bib66","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib67","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib68","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000522547","article-title":"Final results of TACTICS: a Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1053\/j.gastro.2025.03.047_bib69","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-24-0177","article-title":"Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: the PETAL Phase Ib Study","volume":"30","author":"Pinato","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2025.03.047_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.gastro.2025.03.047_bib71","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"The Lancet"},{"key":"10.1053\/j.gastro.2025.03.047_bib72","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"The Lancet"},{"key":"10.1053\/j.gastro.2025.03.047_bib73","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","article-title":"Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma","volume":"31","author":"Zhan","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.gastro.2025.03.047_bib74","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.jvir.2020.07.009","article-title":"Safety and efficacy of locoregional treatment during immunotherapy with nivolumab for hepatocellular carcinoma: a retrospective study of 41 interventions in 29 patients","volume":"31","author":"Marinelli","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.gastro.2025.03.047_bib75","article-title":"Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study [published correction appears in J Immunother Cancer 2023;11:e005457corr1]","volume":"10","author":"de la Torre-Alaez","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.gastro.2025.03.047_bib76","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib77","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1093\/oncolo\/oyad331","article-title":"A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma","volume":"29","author":"Yu","year":"2024","journal-title":"Oncologist"},{"key":"10.1053\/j.gastro.2025.03.047_bib78","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: the NRG Oncology\/RTOG 1112 Phase 3 Randomized Clinical Trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib79","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1200\/JCO-24-01532","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: a randomized, open\u2013label, controlled trial","volume":"43","author":"Xi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib80","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","article-title":"Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study","volume":"70","author":"Wang","year":"2019","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib81","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.cgh.2022.08.023","article-title":"National experience on waitlist outcomes for down-staging of hepatocellular carcinoma: high dropout rate in all-comers","volume":"21","author":"Huang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib82","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib83","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/cancers11081084","article-title":"Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: a proof-of-concept study","volume":"11","author":"Kudo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.gastro.2025.03.047_bib84","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000507370","article-title":"A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements","volume":"9","author":"Kudo","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1053\/j.gastro.2025.03.047_bib85","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib86","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000184","article-title":"Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: a multicenter retrospective comparative study","volume":"7","author":"Moon","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2025.03.047_bib87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1245\/s10434-021-10278-6","article-title":"Stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) as a bridge to transplant in unresectable hepatocellular carcinoma","volume":"29","author":"Verbus","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib88","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233051","article-title":"The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors","volume":"312","author":"Mendiratta-Lala","year":"2024","journal-title":"Radiology"},{"key":"10.1053\/j.gastro.2025.03.047_bib89","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/SLA.0b013e3181961c16","article-title":"A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma","volume":"249","author":"Zhou","year":"2009","journal-title":"Ann Surg"},{"key":"10.1053\/j.gastro.2025.03.047_bib90","doi-asserted-by":"crossref","first-page":"36838","DOI":"10.18632\/oncotarget.5426","article-title":"Hepatic resection alone versus in combination with pre-and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"6","author":"Qi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1053\/j.gastro.2025.03.047_bib91","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ejso.2019.06.031","article-title":"Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: a systematic review and meta-analysis","volume":"45","author":"Chen","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2022.08.019","article-title":"Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy","volume":"175","author":"Wang","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib93","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib94","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.03.047_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2279","article-title":"Updated efficacy and safety data from IMbrave050: phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)","volume":"35","author":"Yopp","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib96","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-18-2641","article-title":"The promise of neoadjuvant immunotherapy and surgery for cancer treatment","volume":"25","author":"O'Donnell","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2025.03.047_bib97","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000430","article-title":"Neoadjuvant and adjuvant systemic therapy in HCC: current status and the future","volume":"8","author":"Singal","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2025.03.047_bib98","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.03.047_bib99","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib101","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis","volume":"25","author":"D'Alessio","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib102","article-title":"Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade. Preprint","author":"Shu","year":"2023","journal-title":"bioRxiv"},{"key":"10.1053\/j.gastro.2025.03.047_bib103","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cgh.2021.07.048","article-title":"National trends and waitlist outcomes of locoregional therapy among liver transplant candidates with hepatocellular carcinoma in the United States","volume":"20","author":"Kwong","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib104","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","article-title":"Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US Multicenter HCC Transplant Consortium","volume":"271","author":"DiNorcia","year":"2020","journal-title":"Ann Surg"},{"key":"10.1053\/j.gastro.2025.03.047_bib105","article-title":"Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma","volume":"7","author":"Tabrizian","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1053\/j.gastro.2025.03.047_bib106","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1053\/j.gastro.2025.03.047_bib107","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1053\/j.gastro.2025.03.047_bib108","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: a multicenter, retrospective cohort study","volume":"24","author":"Guo","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1053\/j.gastro.2025.03.047_bib109","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.03.047_bib110","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ajg.2016.181","article-title":"Hospital volume and survival after hepatocellular carcinoma diagnosis","volume":"111","author":"Mokdad","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.03.047_bib111","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1245\/s10434-013-3413-8","article-title":"Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome","volume":"21","author":"Yopp","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.gastro.2025.03.047_bib112","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000143","article-title":"Multidisciplinary care for patients with HCC: a systematic review and meta-analysis","volume":"7","author":"Seif El Dahan","year":"2023","journal-title":"Hepatol Commun"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525006602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525006602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:09:28Z","timestamp":1778746168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508525006602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":112,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0016508525006602"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2025.03.047","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2025.03.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}